TRENDING TOPICS
1312 articles found for "investing"
The Russell 2000 surged 4.69% in the first week of 2026, outpacing both the S&P 500 and Nasdaq as small-cap stocks finally break out after years of underperformance.
S&P 500 companies spent a record $1.1 trillion on buybacks in 2025, fundamentally reshaping market dynamics. Here's why corporate repurchases have become the market's most powerful tailwind.
Walmart's addition to the Nasdaq-100 index marks a historic moment as the retail giant joins the tech-heavy benchmark, triggering billions in passive fund flows.
Amazon could join the $3 trillion club by year-end 2026, powered by accelerating AWS growth and its massive AI infrastructure investments.
Magnificent Seven earnings growth is expected to slow to 18% in 2026—the weakest since 2022. Here's why this could finally benefit the other 493 S&P 500 stocks.
One year after DeepSeek's bombshell announcement triggered the largest single-day market cap loss in history, the AI landscape looks radically different. Here's what investors learned.
The S&P 500 just posted its third consecutive year of strong gains—a rare feat seen only ten times since 1871. What does history suggest for 2026?
Hedge funds are racing toward $5 trillion in assets while private credit reshapes corporate lending. Inside the forces driving Wall Street's most important transformation.
The S&P 500's forward earnings yield is now nearly equal to Treasury yields—an equity risk premium of just 0.02%. Here's what historic valuations mean for stock investors in 2026.
Macy's is shuttering 14 stores across 12 states as part of its 'Bold New Chapter' strategy. Here's why the 125-year-old retailer is shrinking to survive.
With leveraged long positions in the Russell 2000 at the 94th percentile and markets at record highs, some strategists warn investors may be too complacent.
Radiopharmaceutical developer Aktis Oncology raised $318 million in the first biotech IPO of 2026, with Eli Lilly taking a $100 million stake. The strong debut signals renewed investor appetite for biotech risk.